ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: The BCR-ABL targets are downstream pathways including RAS, PI3K/AKT, and JAK/STAT that address the transformation of healthy cells toward neoplastic cells responsible for CML pathogenesis.